{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:02:03Z","timestamp":1769313723149,"version":"3.49.0"},"reference-count":70,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Acute coronary syndrome (ACS) represents a major cause of death. Bisoprolol is commonly used in the management of ACS. This study aims to investigate the impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on pharmacokinetics and clinical response of bisoprolol in ACS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is an open\u2010label cohort study that included 127 ACS patients and studied the effect of CYP3A5*3, CYP2D6*2A and CYP2D6*4 genotyping using real\u2010time polymerase chain reaction on steady state bisoprolol plasma peak concentration analysed by high performance liquid chromatography\u2013fluorescence detector.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding CYP3A5*3, the mean peak bisoprolol concentration for CC, CT and TT genotypes were 4.25\u2009\u00b1\u20091.20, 3.93\u2009\u00b1\u20091.10 and 1.79\u2009\u00b1\u20090.69\u2009ng\/mL, respectively (<jats:italic>P\u2009&lt;<\/jats:italic>\u2009.001). Higher systolic (126\u2009\u00b1\u20095.47 mmHg), diastolic blood pressure (82\u2009\u00b1\u20092.73 mmHg) and heart rate (97.80\u2009\u00b1\u20093.03 beats\/min) were also observed in CYP3A5*3 TT carriers (<jats:italic>P\u2009&lt;<\/jats:italic>\u2009.05). In CYP2D6*2A, the peak concentration of bisoprolol was lower in CC carriers (3.54\u2009\u00b1\u20091 ng\/mL) compared to GG (4.38\u2009\u00b1\u20091.25 ng\/mL) and GC carriers (4.07\u2009\u00b1\u20091.29 ng\/mL, <jats:italic>P\u2009=<\/jats:italic>\u2009.019). In CYP2D6*4, the mean bisoprolol peak concentration in CC carriers was 3.98\u2009\u00b1\u20091.31 ng\/mL, which was lower than T allele carriers (4.5\u2009\u00b1\u20090.8, <jats:italic>P\u2009=<\/jats:italic>\u2009.02). No differences in heart rate, systolic, diastolic blood pressure or bisoprolol dose were observed among CYP2D6*2A or CYP2D6*4 variants. Smokers exhibited lower bisoprolol peak concentration (3.96\u2009\u00b1\u20091.2 ng\/mL) compared to nonsmokers (4.55\u2009\u00b1\u20091.34 ng\/mL, <jats:italic>P\u2009=<\/jats:italic>\u2009.037).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is an association between CYP3A5*3, CYP2D6*4, CYP2D6*2A variants and bisoprolol peak concentration, which may serve as a guide in the future in choosing the optimum dose of bisoprolol in ACS patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16134","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T01:25:05Z","timestamp":1718673905000},"page":"2539-2553","source":"Crossref","is-referenced-by-count":2,"title":["Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients"],"prefix":"10.1111","volume":"90","author":[{"given":"Sherouk M.","family":"Okda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy Damanhour University  Damanhour Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha A.","family":"El\u2010Bassiouny","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy Damanhour University  Damanhour Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mahmoud","family":"El Amrawy","sequence":"additional","affiliation":[{"name":"Cardiology Department, Faculty of Medicine Alexandria University  Alexandria Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Salahuddin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy Damanhour University  Damanhour Egypt"},{"name":"Department of Biochemistry College of Pharmacy, Al\u2010Ayen Iraqi University  Thi\u2010Qar Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohila M.","family":"Elonsy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Damanhour University  Damanhour Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-6036","authenticated-orcid":false,"given":"Amira B.","family":"Kassem","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy Damanhour University  Damanhour Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101622"},{"key":"e_1_2_12_3_1","first-page":"1","volume-title":"Coronary Artery Disease: New Approaches without Traditional Revascularization","author":"Barsness GW","year":"2014"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S26414"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066613503294"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs184"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2015.03.002"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31827caa64"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.10.050"},{"key":"e_1_2_12_10_1","unstructured":"Acute coronary syndromes NICE guideline. [cited 2023 Jun 5];2020Available from:www.nice.org.uk\/guidance\/ng185"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1363729"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.09.044"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/heartviews.heartviews_75_22"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07205-y"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552\u20104604.1986.tb02959.x"},{"issue":"11","key":"e_1_2_12_16_1","first-page":"S2","article-title":"High beta 1\u2010selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol","volume":"8","author":"Haeusler G","year":"1986","journal-title":"J Cardiovasc Pharmacol [Internet]"},{"key":"e_1_2_12_17_1","first-page":"3694","volume-title":"Martindale: the complete drug reference","author":"Sweetman SC","year":"2009"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000802"},{"key":"e_1_2_12_19_1","first-page":"249","article-title":"Chromosomal region 11p14.1 is associated with pharmacokinetics and pharmacodynamics of bisoprolol","volume":"15","author":"Fontana V","year":"2022","journal-title":"Pharmgenomics Pers Med [Internet]"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195\u2010668X(02)00743\u20101"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr020"},{"issue":"2","key":"e_1_2_12_22_1","first-page":"216","article-title":"Impact of different dosage of bisoprolol on T lymphocyte subsets and cardiac function in the treatment of coronary heart disease patients complicated with heart failure","volume":"18","author":"Xiang G","year":"2018","journal-title":"J Trop Med (Guangzhou)"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1134\/S2079057021040135"},{"issue":"10","key":"e_1_2_12_24_1","first-page":"2727","article-title":"Bisoprolol responses (PK\/PD) in hypertensive patients: a cytochrome P450 (CYP) 2D6 targeted polymorphism study. Saudi","volume":"27","author":"Mohammed Alkreathy H","year":"2020","journal-title":"Aust J Biol Sci"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.20996\/1819\u20106446\u20102022\u201008\u201006"},{"key":"e_1_2_12_26_1","first-page":"1529","article-title":"Influence of CYP2D6 and CYP3A5 polymorphisms on the pharmacokinetics and pharmacodynamics of bisoprolol in hypertensive Chinese patients","volume":"8","author":"Chan SW","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0015"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"issue":"3","key":"e_1_2_12_30_1","first-page":"39","article-title":"Acute coronary syndrome registry","volume":"14","author":"Ragy HI","year":"2017","journal-title":"Life Sci J [Internet]"},{"issue":"2","key":"e_1_2_12_31_1","first-page":"114","article-title":"Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndrome: final data of the nationwide cross\u2010sectional \u2018CardioRisk\u2019 project","volume":"11","author":"Reda A","year":"2020","journal-title":"J Public Health Afr [Internet]"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejccm.2014.07.001"},{"issue":"0","key":"e_1_2_12_33_1","first-page":"0","article-title":"Novel potential drug interactions with bisoprolol in hospitalized acute coronary syndrome patients","volume":"0","author":"Okda S","year":"2024","journal-title":"Bull Pharmaceut Sci Assiut Univ [Internet]"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2010.73"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0162-1"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f3c063"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-017-0011-3"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086114"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.199"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.06.33"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.201217.001"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112069"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024\u20103205(98)00371\u20103"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/js970316d"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01293-4"},{"key":"e_1_2_12_46_1","doi-asserted-by":"crossref","unstructured":"LeeSJ GoldsteinJA.Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. [Internet].2005Nov 24 [cited 2023 May 8];6(4):357\u201371. Available from:https:\/\/www.futuremedicine.com\/doi\/10.1517\/14622416.6.4.357","DOI":"10.1517\/14622416.6.4.357"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-005-3185-5"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/B978-0-12-803412-5.00008-2","article-title":"Endocrinology and disorders of the reproductive system","author":"Corenblum B","year":"2017","journal-title":"Endocr Biomark: Clin Clin Chem Partnership"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/73.5.658"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.22.328"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200e991"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073405"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13388"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112797"},{"issue":"1","key":"e_1_2_12_55_1","first-page":"1","article-title":"Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population","volume":"23","author":"Akil S","year":"2022","journal-title":"Egypt J Medical Human Gen [Internet]"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215617563"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2010.05.006"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/2048872616672077"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005371"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v4.i1.15"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2011.08.025"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.07.005"},{"key":"e_1_2_12_63_1","article-title":"CYP3A5 gene\u2010guided tacrolimus treatment of living\u2010donor Egyptian kidney transplanted patients","volume":"11","author":"Mendrinou E","year":"2020","journal-title":"Front Pharmacol [Internet]"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2007.05.012"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq374"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320093"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705786"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.legalmed.2012.09.004"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198917010-00005"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262180-00017"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000644"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:04:33Z","timestamp":1750305873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bcp.16134"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16134","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}